NCT06814938View on ClinicalTrials.gov

A Study of a Novel Precision Medicine Approach for Obesity

PHASE4RecruitingINTERVENTIONAL
Enrollment

135

Participants

Timeline

Start Date

February 21, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

November 30, 2028

Conditions
Obesity
Interventions
DRUG

Semaglutide

2.4 mg subcutaneous weekly

DRUG

Placebo

Looks exactly like the study drug, but it contains no active ingredient administered subcutaneous weekly

Trial Locations (2)

32224

RECRUITING

Mayo Clinic in Florida, Jacksonville

55905

RECRUITING

Mayo Clinic in Rochester, Rochester

Sponsors

Lead Sponsor

Mayo Clinic

Collaborators (1)

Phenomix Sciences
All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

collaborator

Phenomix Sciences

UNKNOWN

lead

Mayo Clinic

OTHER